The University of Arizona Division of Developmental & Behavioral Pediatrics has partnered with Axial Therapeutics for a clinical trial to determine whether its investigational drug, AB-2004, is safe and effective in treating the symptoms of autism spectrum disorder in children ages 5-17. This 12-week randomized, double-blind, placebo-controlled study includes behavioral assessments and safety monitoring. Blood draws, urine and stool samples are required.
